Use of Biologics in Private Practice: Nine Years of Lessons and Learning. Correa-Selm, L. M., Alamgir, M., & Rao, B. K. J Drugs Dermatol, 16(3):215–217, March, 2017. ![Use of Biologics in Private Practice: Nine Years of Lessons and Learning [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper abstract bibtex \textlessp\textgreaterOver a decade ago, the FDA approved biologics for psoriasis, which changed how the disease is treated and, in most cases, has a significant positive impact on the lives of patients. Side effects primarily identified during the investigational and research phase led to the development of specific guidelines for treatment. The treatment guidelines have been amended to incorporate better understandings of side-effects over the years that the disease has been treated. In this study, we focused on a chart review that included assessing the current guidelines and their alignment with modern patient management and the recent side effects presented. This life-cycle evaluation included over 100 patients, management of their treatment, laboratory abnormalities, criteria for choosing or changing to a different biologic, and the effects of the treatments management throughout the years. The review identified some recommended changes in the application and treatment of psoriasis with biologics. To further evidence our findings, we hope to expand this study to a larger scale with more patients.\textless/p\textgreater \textlessp\textgreater\textlessem\textgreaterJ Drugs Dermatol. 2017;16(3):215-217.\textless/em\textgreater\textless/p\textgreater.
@article{correa-selm_use_2017,
title = {Use of {Biologics} in {Private} {Practice}: {Nine} {Years} of {Lessons} and {Learning}},
volume = {16},
copyright = {All rights reserved},
issn = {1545-9616 (Print) 1545-9616 (Linking)},
url = {https://www.ncbi.nlm.nih.gov/pubmed/28301616},
abstract = {{\textless}p{\textgreater}Over a decade ago, the FDA approved biologics for psoriasis, which changed how the disease is treated and, in most cases, has a significant positive impact on the lives of patients. Side effects primarily identified during the investigational and research phase led to the development of specific guidelines for treatment. The treatment guidelines have been amended to incorporate better understandings of side-effects over the years that the disease has been treated. In this study, we focused on a chart review that included assessing the current guidelines and their alignment with modern patient management and the recent side effects presented. This life-cycle evaluation included over 100 patients, management of their treatment, laboratory abnormalities, criteria for choosing or changing to a different biologic, and the effects of the treatments management throughout the years. The review identified some recommended changes in the application and treatment of psoriasis with biologics. To further evidence our findings, we hope to expand this study to a larger scale with more patients.{\textless}/p{\textgreater} {\textless}p{\textgreater}{\textless}em{\textgreater}J Drugs Dermatol. 2017;16(3):215-217.{\textless}/em{\textgreater}{\textless}/p{\textgreater}.},
number = {3},
journal = {J Drugs Dermatol},
author = {Correa-Selm, L. M. and Alamgir, M. and Rao, B. K.},
month = mar,
year = {2017},
keywords = {Adolescent, Adult, Aged, Aged, 80 and over, Biological Products/administration \& dosage/adverse effects/*therapeutic use, Child, Female, Humans, Male, Middle Aged, Practice Guidelines as Topic, Private Practice/*trends, Psoriasis/blood/*drug therapy, Quality of Life, Retrospective Studies, Severity of Illness Index, Young Adult},
pages = {215--217},
}
Downloads: 0
{"_id":"2c2jEgaEbEfBShocg","bibbaseid":"correaselm-alamgir-rao-useofbiologicsinprivatepracticenineyearsoflessonsandlearning-2017","author_short":["Correa-Selm, L. M.","Alamgir, M.","Rao, B. K."],"bibdata":{"bibtype":"article","type":"article","title":"Use of Biologics in Private Practice: Nine Years of Lessons and Learning","volume":"16","copyright":"All rights reserved","issn":"1545-9616 (Print) 1545-9616 (Linking)","url":"https://www.ncbi.nlm.nih.gov/pubmed/28301616","abstract":"\\textlessp\\textgreaterOver a decade ago, the FDA approved biologics for psoriasis, which changed how the disease is treated and, in most cases, has a significant positive impact on the lives of patients. Side effects primarily identified during the investigational and research phase led to the development of specific guidelines for treatment. The treatment guidelines have been amended to incorporate better understandings of side-effects over the years that the disease has been treated. In this study, we focused on a chart review that included assessing the current guidelines and their alignment with modern patient management and the recent side effects presented. This life-cycle evaluation included over 100 patients, management of their treatment, laboratory abnormalities, criteria for choosing or changing to a different biologic, and the effects of the treatments management throughout the years. The review identified some recommended changes in the application and treatment of psoriasis with biologics. To further evidence our findings, we hope to expand this study to a larger scale with more patients.\\textless/p\\textgreater \\textlessp\\textgreater\\textlessem\\textgreaterJ Drugs Dermatol. 2017;16(3):215-217.\\textless/em\\textgreater\\textless/p\\textgreater.","number":"3","journal":"J Drugs Dermatol","author":[{"propositions":[],"lastnames":["Correa-Selm"],"firstnames":["L.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Alamgir"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Rao"],"firstnames":["B.","K."],"suffixes":[]}],"month":"March","year":"2017","keywords":"Adolescent, Adult, Aged, Aged, 80 and over, Biological Products/administration & dosage/adverse effects/*therapeutic use, Child, Female, Humans, Male, Middle Aged, Practice Guidelines as Topic, Private Practice/*trends, Psoriasis/blood/*drug therapy, Quality of Life, Retrospective Studies, Severity of Illness Index, Young Adult","pages":"215–217","bibtex":"@article{correa-selm_use_2017,\n\ttitle = {Use of {Biologics} in {Private} {Practice}: {Nine} {Years} of {Lessons} and {Learning}},\n\tvolume = {16},\n\tcopyright = {All rights reserved},\n\tissn = {1545-9616 (Print) 1545-9616 (Linking)},\n\turl = {https://www.ncbi.nlm.nih.gov/pubmed/28301616},\n\tabstract = {{\\textless}p{\\textgreater}Over a decade ago, the FDA approved biologics for psoriasis, which changed how the disease is treated and, in most cases, has a significant positive impact on the lives of patients. Side effects primarily identified during the investigational and research phase led to the development of specific guidelines for treatment. The treatment guidelines have been amended to incorporate better understandings of side-effects over the years that the disease has been treated. In this study, we focused on a chart review that included assessing the current guidelines and their alignment with modern patient management and the recent side effects presented. This life-cycle evaluation included over 100 patients, management of their treatment, laboratory abnormalities, criteria for choosing or changing to a different biologic, and the effects of the treatments management throughout the years. The review identified some recommended changes in the application and treatment of psoriasis with biologics. To further evidence our findings, we hope to expand this study to a larger scale with more patients.{\\textless}/p{\\textgreater} {\\textless}p{\\textgreater}{\\textless}em{\\textgreater}J Drugs Dermatol. 2017;16(3):215-217.{\\textless}/em{\\textgreater}{\\textless}/p{\\textgreater}.},\n\tnumber = {3},\n\tjournal = {J Drugs Dermatol},\n\tauthor = {Correa-Selm, L. M. and Alamgir, M. and Rao, B. K.},\n\tmonth = mar,\n\tyear = {2017},\n\tkeywords = {Adolescent, Adult, Aged, Aged, 80 and over, Biological Products/administration \\& dosage/adverse effects/*therapeutic use, Child, Female, Humans, Male, Middle Aged, Practice Guidelines as Topic, Private Practice/*trends, Psoriasis/blood/*drug therapy, Quality of Life, Retrospective Studies, Severity of Illness Index, Young Adult},\n\tpages = {215--217},\n}\n\n\n\n","author_short":["Correa-Selm, L. M.","Alamgir, M.","Rao, B. K."],"key":"correa-selm_use_2017","id":"correa-selm_use_2017","bibbaseid":"correaselm-alamgir-rao-useofbiologicsinprivatepracticenineyearsoflessonsandlearning-2017","role":"author","urls":{"Paper":"https://www.ncbi.nlm.nih.gov/pubmed/28301616"},"keyword":["Adolescent","Adult","Aged","Aged","80 and over","Biological Products/administration & dosage/adverse effects/*therapeutic use","Child","Female","Humans","Male","Middle Aged","Practice Guidelines as Topic","Private Practice/*trends","Psoriasis/blood/*drug therapy","Quality of Life","Retrospective Studies","Severity of Illness Index","Young Adult"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/raoresearch","dataSources":["5i38dLwPk6C3jurSL","aGgndugSyribdb2rd","2tgmyzKov4y6MHvQs"],"keywords":["adolescent","adult","aged","aged","80 and over","biological products/administration & dosage/adverse effects/*therapeutic use","child","female","humans","male","middle aged","practice guidelines as topic","private practice/*trends","psoriasis/blood/*drug therapy","quality of life","retrospective studies","severity of illness index","young adult"],"search_terms":["use","biologics","private","practice","nine","years","lessons","learning","correa-selm","alamgir","rao"],"title":"Use of Biologics in Private Practice: Nine Years of Lessons and Learning","year":2017}